MX2017010682A - Metodos y composiciones para disminuir el vaciado gastrico. - Google Patents

Metodos y composiciones para disminuir el vaciado gastrico.

Info

Publication number
MX2017010682A
MX2017010682A MX2017010682A MX2017010682A MX2017010682A MX 2017010682 A MX2017010682 A MX 2017010682A MX 2017010682 A MX2017010682 A MX 2017010682A MX 2017010682 A MX2017010682 A MX 2017010682A MX 2017010682 A MX2017010682 A MX 2017010682A
Authority
MX
Mexico
Prior art keywords
gastric emptying
compositions
methods
decreasing gastric
decreasing
Prior art date
Application number
MX2017010682A
Other languages
English (en)
Inventor
J Kyle Donald
Hummel Michele
Whiteside Garth
Lautermilch Nathan
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of MX2017010682A publication Critical patent/MX2017010682A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

En determinadas modalidades se describe un método para disminuir el vaciado gástrico que comprende administrar a un sujeto una cantidad eficaz de un bloqueador de canal de sodio para disminuir el vaciado gástrico.
MX2017010682A 2015-02-19 2016-02-19 Metodos y composiciones para disminuir el vaciado gastrico. MX2017010682A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562118268P 2015-02-19 2015-02-19
PCT/US2016/018715 WO2016134283A1 (en) 2015-02-19 2016-02-19 Methods and compositions for decreasing gastric emptying

Publications (1)

Publication Number Publication Date
MX2017010682A true MX2017010682A (es) 2018-04-24

Family

ID=56689101

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010682A MX2017010682A (es) 2015-02-19 2016-02-19 Metodos y composiciones para disminuir el vaciado gastrico.

Country Status (12)

Country Link
US (2) US9763955B2 (es)
EP (1) EP3258925B1 (es)
JP (1) JP6762308B2 (es)
KR (1) KR20170117170A (es)
CN (1) CN107613965A (es)
AU (1) AU2016219879A1 (es)
BR (1) BR112017017619A2 (es)
CA (1) CA2977367A1 (es)
IL (1) IL253949A0 (es)
MX (1) MX2017010682A (es)
PH (1) PH12017501393A1 (es)
WO (1) WO2016134283A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2593434A1 (en) 2010-07-16 2013-05-22 Purdue Pharma LP Pyridine compounds as sodium channel blockers
ES2570784T3 (es) 2010-12-22 2016-05-20 Purdue Pharma Lp Piridinas sustituidas como bloqueadores de los canales de sodio
SI2753606T1 (sl) 2011-09-02 2017-10-30 Purdue Pharma Lp Pirimidini kot blokatorji natrijevih kanalov
EP2935257B1 (en) 2012-12-20 2018-02-07 Purdue Pharma LP Cyclic sulfonamides as sodium channel blockers
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
EP3039019B1 (en) 2013-08-26 2020-04-22 Purdue Pharma L.P. Azaspiro[4.5]decane derivatives and use thereof
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
JP6337124B2 (ja) 2013-12-23 2018-06-06 パーデュー、ファーマ、リミテッド、パートナーシップ インダゾール及びその使用
EP3087073B1 (en) 2013-12-26 2018-07-04 Purdue Pharma LP 10-substituted morphinan hydantoins
WO2015112801A1 (en) 2014-01-24 2015-07-30 Purdue Pharma L.P. Pyridines and pyrimidines and use thereof
KR20170117170A (ko) * 2015-02-19 2017-10-20 퍼듀 퍼머 엘피 위 배출을 감소시키기 위한 방법 및 조성물
CN106397426A (zh) * 2016-03-29 2017-02-15 广东环境保护工程职业学院 一种1，3，4-噻二唑类化合物及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017490C1 (ru) 1990-01-18 1994-08-15 Назаренко Петр Михайлович Способ лечения демпин-синдрома после резекции желудка по способу бильрот-1
DE69635048T2 (de) 1995-06-12 2006-02-16 G.D. Searle & Co. Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US20040038970A1 (en) * 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
PL214230B1 (pl) 2000-03-24 2013-07-31 Euro Celtique Sa Podstawione arylem pirazole i triazole, kompozycja farmaceutyczna je zawierajaca oraz ich zastosowanie
NZ521870A (en) 2000-03-31 2004-08-27 Euro Celtique S Aminopyridines and their use as anticonvulsants and sodium channel blockers
WO2003008398A1 (en) 2001-07-16 2003-01-30 Euro-Celtique S.A. Aryl substituted thiazolidinones and the use thereof
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
KR20040099324A (ko) 2002-03-13 2004-11-26 유로-셀티큐 에스.에이. 아릴 치환된 피리미딘 및 이것의 용도
EA200500289A1 (ru) 2002-07-31 2005-06-30 Еуро-Селтик С. А. Арилзамещенные бензимидазолы и их использование в качестве блокаторов натриевых каналов
CA2514574A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
EP1533298A1 (en) * 2003-11-21 2005-05-25 Newron Pharmaceuticals S.p.A. 3-aminopyrrolidone derivatives
CA2595486A1 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20070020194A1 (en) * 2005-06-08 2007-01-25 Greenway Frank L Iii Nasally administered appetite suppressant
WO2007083239A1 (en) 2006-01-23 2007-07-26 Pfizer Limited Pyridine derivatives as sodium channel modulators
EP2078523A4 (en) * 2006-10-13 2010-02-10 Ajinomoto Kk AGENT COMPRISING 4-HYDROXYISOLEUCINE FOR THE SUPPRESSION OF GASTRIC DRAIN
PL2079485T3 (pl) 2006-11-01 2012-12-31 Purdue Pharma Lp Związki fenylopropionamidu i ich zastosowanie
JP5463285B2 (ja) 2007-07-13 2014-04-09 アイカジェン， インコーポレイテッド ナトリウムチャネル阻害物質
CA2693588C (en) 2007-07-13 2015-11-17 Icagen, Inc. Sodium channel inhibitors
JP2013530180A (ja) 2010-06-16 2013-07-25 パーデュー、ファーマ、リミテッド、パートナーシップ アリール置換インドールおよびその使用
WO2012004664A2 (en) 2010-07-07 2012-01-12 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
EP2593434A1 (en) 2010-07-16 2013-05-22 Purdue Pharma LP Pyridine compounds as sodium channel blockers
JP2013538227A (ja) 2010-09-17 2013-10-10 パーデュー、ファーマ、リミテッド、パートナーシップ ピリジン化合物およびその使用
ES2540562T3 (es) 2010-10-05 2015-07-10 Purdue Pharma L.P. Compuestos de quinazolina como bloqueadores de canales de sodio
ES2570784T3 (es) 2010-12-22 2016-05-20 Purdue Pharma Lp Piridinas sustituidas como bloqueadores de los canales de sodio
SI2753606T1 (sl) * 2011-09-02 2017-10-30 Purdue Pharma Lp Pirimidini kot blokatorji natrijevih kanalov
MX337469B (es) 2011-10-26 2016-03-02 Pfizer Ltd Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio.
WO2013064884A1 (en) 2011-10-31 2013-05-10 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
WO2013072758A1 (en) 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
JP5938219B2 (ja) * 2012-01-23 2016-06-22 株式会社明治 胃排出遅延のための食品用の剤または医療用の剤
WO2013136170A1 (en) 2012-03-16 2013-09-19 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
US9718865B2 (en) 2012-07-27 2017-08-01 Purdue Pharma L.P. Sodium channel blocking peptides and the use thereof
EP2964639B1 (en) 2013-03-04 2018-05-02 Purdue Pharma LP Pyrimidine carboxamides as sodium channel blockers
CA3082427A1 (en) 2013-03-15 2014-09-25 Purdue Pharma L.P. Carboxamide derivatives and use thereof
KR20170117170A (ko) * 2015-02-19 2017-10-20 퍼듀 퍼머 엘피 위 배출을 감소시키기 위한 방법 및 조성물

Also Published As

Publication number Publication date
WO2016134283A1 (en) 2016-08-25
AU2016219879A1 (en) 2017-08-24
US20160243129A1 (en) 2016-08-25
CN107613965A (zh) 2018-01-19
US20170340646A1 (en) 2017-11-30
BR112017017619A2 (pt) 2018-05-08
PH12017501393A1 (en) 2018-01-08
EP3258925A4 (en) 2019-01-09
US9763955B2 (en) 2017-09-19
CA2977367A1 (en) 2016-08-25
IL253949A0 (en) 2017-10-31
JP6762308B2 (ja) 2020-09-30
EP3258925B1 (en) 2023-03-29
US10143696B2 (en) 2018-12-04
JP2018509397A (ja) 2018-04-05
EP3258925A1 (en) 2017-12-27
KR20170117170A (ko) 2017-10-20

Similar Documents

Publication Publication Date Title
PH12017501393A1 (en) Methods and compositions for decreasing gastric emptying
SG11201608062VA (en) Method for preventing or reducing engine knock and pre-ignition
PH12014501453B1 (en) Method of reducing exercise-induced joint pain in non-arthritic mammals
EP3134130A4 (en) Compositions and methods to treating hemoglobinopathies
EP2974690A4 (en) DENTAL PROSTHESES DESIGN PROGRAM, DENTAL PROSTHESES DESIGN DEVICE, AND DENTAL PROSTHESES DESIGN METHOD
MX2021010460A (es) Metodo de tratamiento con tradipitant.
EP3099225A4 (en) Device and method to treat vaginal atrophy
HK1217650A1 (zh) 用於治療劇痛的組合物及方法
MY178990A (en) Siloxane compositions and methods for reducing voc and siloxane dust
EP3054930A4 (en) Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
IL249662A0 (en) Tampon and method for preparation
EP3193651A4 (en) Castless stance corrected prostetic and method of forming same
SG10201709955PA (en) Methods of treatment and compositions with xanthine oxidase inhibitors
MY175326A (en) Product and method for treating diarrhea
ZA201707663B (en) Friction reducing terpolymer compositions and method of fracturing
NZ709664A (en) Use of fenugreek extract to enhance female libido
GEP20217236B (en) Composition comprising pentose and polyphenolic compound
MX2019012659A (es) Metodos para tratar ateroesclerosis con neutralizadores gamma-cetoaldehido.
EP3038645A4 (en) Method for prophylaxis and/or treatment of erbb2 positive cancers
MX2016016039A (es) Formulacion farmaceutica para reducir la frecuencia de micción y método para su utilización..
MA40333A (fr) Systèmes et méthodes pour atténuer une euphorie induite par des opioïdes
EP3080246A4 (en) Compositions and methods for producing and administering brown adipocytes
EP3016981A4 (en) Compositions and methods for treatment of stroke
HK1223555A1 (zh) 用於減少眼內壓的組合物和方法
EP3240562A4 (en) Compositions and methods for delivering lypophilic agents to dental pulp and for enhancing dentin production